This Month in Psychopharmacology

Adult ADHD and Dementia

Every year NEI Fall Congress kicks off with multiple pre-conference...

Read More

Brief, Culturally Sensitive Screener Helps Primary Care Providers Diagnose Dementia

A brief and culturally fair cognitive assessment tool, paired with ...

Read More

FDA Approves New Alzheimer's Treatment

The U.S. Food and Drug Administration has approved a new treatment ...

Read More

Highlights from 2024 NEI Synapse: Memories in the Future: An Update on the Diagnosis and Treatment of Alzheimer’s Disease

In her 2024 NEI Synapse presentation, Dr. Dani Cabral enlightened t...

Read More

Erectile Dysfunction Drugs May Protect Against Alzheimer’s

With Alzheimer’s disease (AD) cases projected to reach 157 million ...

Read More

Blood Test Predicts Who Might Benefit Most From Anti-Amyloid Drugs

The widely accepted Amyloid Cascade Hypothesis indicates that the m...

Read More

Gut Microbiome Composition May be an Indicator of Preclinical Alzheimer’s Disease

With Alzheimer’s disease (AD) becoming a global crisis, as lifespan...

Read More

Sleep-Disordered Breathing Tied to Brain Volumes in Amyloid-Positive Older Adults

Sleep-disordered breathing (SDB) has been associated with increased...

Read More

FDA Approves First Treatment for Agitation Associated with Alzheimer’s Dementia

The U.S. Food and Drug Administration (FDA) has approved the supple...

Read More

Blood Test Predicts Which People With Amyloid Are Likely to Decline Cognitively

The pathology of Alzheimer’s disease (AD) begins with a prolonged p...

Read More

The Future of Psychopharmacology

It is an incredible time in terms of the development of new psychop...

Read More

FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment

The U.S. Food and Drug Administration recently approved lecanemab, ...

Read More